PSNL - Cancer test developer Personalis to cut 65 jobs to reduce costs
2023-12-01 17:09:11 ET
More on Personalis
- Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript
- Personalis: Collaborations Should Ignite Growth Narrative
- Personalis to issue 9.2M shares as Tempus joins hands for cancer test
- Personalis GAAP EPS of -$0.60 misses by $0.08, revenue of $18.2M beats by $1.22M
- Seeking Alpha’s Quant Rating on Personalis
For further details see:
Cancer test developer Personalis to cut 65 jobs to reduce costs